Published in Nat Rev Cancer on June 01, 2013
Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration. Sci Signal (2014) 1.60
Screening for Chemical Contributions to Breast Cancer Risk: A Case Study for Chemical Safety Evaluation. Environ Health Perspect (2015) 1.44
Early dissemination seeds metastasis in breast cancer. Nature (2016) 1.20
Is progesterone a neutral or protective factor for breast cancer? Nat Rev Cancer (2014) 1.07
BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol (2014) 1.03
Progesterone and Wnt4 control mammary stem cells via myoepithelial crosstalk. EMBO J (2015) 1.00
Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol (2015) 0.98
Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis. Endocrinology (2015) 0.96
Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer. Oncotarget (2015) 0.94
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine (2015) 0.93
Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med (2014) 0.92
Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther (2013) 0.91
Elevation of SIPL1 (SHARPIN) Increases Breast Cancer Risk. PLoS One (2015) 0.88
Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Oncotarget (2014) 0.84
Relationship between nucleosome positioning and progesterone-induced alternative splicing in breast cancer cells. RNA (2015) 0.83
Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv (2016) 0.80
Regulation of mammary epithelial cell homeostasis by lncRNAs. Int J Biochem Cell Biol (2014) 0.79
Tissue-specific tumor suppression by BRCA1. Proc Natl Acad Sci U S A (2014) 0.79
Human breast progenitor cell numbers are regulated by WNT and TBX3. PLoS One (2014) 0.78
Sexual dimorphism in cancer. Nat Rev Cancer (2016) 0.78
Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts. Springerplus (2015) 0.77
Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells. PLoS One (2014) 0.77
Paracrine Met signaling triggers epithelial-mesenchymal transition in mammary luminal progenitors, affecting their fate. Elife (2015) 0.76
A cell-autonomous molecular cascade initiated by AMP-activated protein kinase represses steroidogenesis. Mol Cell Biol (2014) 0.76
Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res (2015) 0.76
Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression. PLoS One (2015) 0.76
RNPC1 enhances progesterone receptor functions by regulating its mRNA stability in breast cancer. Oncotarget (2017) 0.76
An ex vivo model to study hormone action in the human breast. J Vis Exp (2015) 0.76
In-silico insights on the prognostic potential of immune cell infiltration patterns in the breast lobular epithelium. Sci Rep (2016) 0.75
Tumor suppressor SPOP mediates the proteasomal degradation of progesterone receptors (PRs) in breast cancer cells. Am J Cancer Res (2015) 0.75
Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes. BMC Cancer (2016) 0.75
Reply to Is progesterone a neutral or protective factor for breast cancer? Nat Rev Cancer (2014) 0.75
Breast carcinoma associated with prolactinoma: A case report. Cancer Biol Ther (2017) 0.75
PGRMC1 Elevation in Multiple Cancers and Essential Role in Stem Cell Survival. Adv Lung Cancer (Irvine) (2016) 0.75
Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. Oncotarget (2015) 0.75
Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes. Breast Cancer Res (2014) 0.75
Peroral Estradiol Is Sufficient to Induce Carcinogen-Induced Mammary Tumorigenesis in Ovariectomized Rats without Progesterone. PLoS One (2016) 0.75
Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. J Hematol Oncol (2017) 0.75
Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor. Oncol Lett (2015) 0.75
Dissecting the Biology of Menstrual Cycle-Associated Breast Cancer Risk. Front Oncol (2016) 0.75
The molecular landscape of the normal human breast--defining normal. Breast Cancer Res (2014) 0.75
Interferon-Stimulated Genes are Transcriptionally Repressed by PR in Breast Cancer. Mol Cancer Res (2017) 0.75
Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models. J Steroid Biochem Mol Biol (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
Mammographic density and the risk and detection of breast cancer. N Engl J Med (2007) 14.32
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 10.35
Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell (1982) 9.29
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev (1995) 7.16
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell (1988) 6.48
Distinct stem cells contribute to mammary gland development and maintenance. Nature (2011) 6.32
Age at first birth and breast cancer risk. Bull World Health Organ (1970) 6.16
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
Minireview: Cyclin D1: normal and abnormal functions. Endocrinology (2004) 5.22
Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development (2000) 5.03
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res (2005) 4.79
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell (2003) 4.67
Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst (2004) 4.57
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst (2003) 3.83
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature (1983) 3.63
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol (2011) 3.36
Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A (2006) 3.32
Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev (2000) 3.30
Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A (2003) 3.30
Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol (2006) 3.24
A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci U S A (1998) 3.23
Developmental stage and time dictate the fate of Wnt/β-catenin-responsive stem cells in the mammary gland. Cell Stem Cell (2012) 3.17
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell (2001) 3.10
Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem (2001) 3.07
Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors. J Exp Med (1959) 2.92
Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer (1987) 2.73
Assessing reproductive status/stages in mice. Curr Protoc Neurosci (2009) 2.63
Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science (2000) 2.57
Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol (2012) 2.56
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A (2010) 2.45
Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev Dyn (2006) 2.35
Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci U S A (2007) 2.32
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer (2005) 2.32
Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat (1999) 2.30
Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol (1999) 2.22
On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst (1973) 2.15
Endocrine control of mammarygland development and function in the C3H/ He Crgl mouse. J Natl Cancer Inst (1958) 2.14
The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev (2008) 2.13
C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. Mol Endocrinol (2000) 2.11
Hormone action in the mammary gland. Cold Spring Harb Perspect Biol (2010) 2.10
Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med (2013) 2.09
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res (2012) 1.98
Hormonal synergism in mammary growth. Proc R Soc Lond B Biol Sci (1958) 1.84
IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell (2002) 1.79
Lactoferrin expression in the mouse reproductive tract during the natural estrous cycle: correlation with circulating estradiol and progesterone. Endocrinology (1992) 1.75
Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics (2008) 1.70
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab (1999) 1.63
Direct action of 17 beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Res (1987) 1.59
Cyclic Variation of DNA synthesis in human breast epithelium. J Natl Cancer Inst (1977) 1.56
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat (2007) 1.55
A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol (1986) 1.46
Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. Mol Endocrinol (2002) 1.37
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer (2004) 1.36
Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology (2005) 1.35
Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. Am J Pathol (2005) 1.35
Transcriptional response of the murine mammary gland to acute progesterone exposure. Endocrinology (2008) 1.33
Case-control study of increased mammographic breast density response to hormone replacement therapy. Cancer Epidemiol Biomarkers Prev (2002) 1.28
Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. Endocrinology (2007) 1.27
Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol (2007) 1.25
Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis (1996) 1.19
Effect of oestradiol on progesterone receptors in normal mammary glands and its relationship with lactation. Biochem J (1979) 1.16
Pharmacological profile of progestins. Maturitas (2004) 1.15
Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol (2002) 1.12
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res (2008) 1.11
Progesterone action in normal mouse mammary gland. Endocrinology (1990) 1.05
Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol (2005) 1.04
Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol (2010) 1.02
High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int J Cancer (2010) 1.02
Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm Cancer (2010) 0.99
Alternative 5'-untranslated first exons of the mouse Cyp19A1 (aromatase) gene. J Steroid Biochem Mol Biol (2009) 0.90
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. Breast Cancer Res Treat (2012) 0.88
An expression study of hormone receptors in spontaneously developed, carcinogen-induced and hormone-induced mammary tumors in female Noble rats. Int J Oncol (2003) 0.87
ID4 regulates mammary gland development by suppressing p38MAPK activity. Development (2011) 0.86
Preview: MCE special issue on molecular mechanisms of action in progesterone signalling. Mol Cell Endocrinol (2012) 0.78